Enzyme – Page 2 – Talk Bio

Actionable Insights Powered by AI

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

4 months ago talkbio0Tagged CDK2 protein, human, Gilead, Kymera, Molecular Glue Degrader, Neoplasms, protein degrader, sanofi

Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader

Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio

4 months ago talkbio0Tagged Acquisition, Cardiovascular Diseases, eli lilly, Gene Modification, Heart Diseases, PCSK9 protein, human, VERVE-102

Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

5 months ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

5 months ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

5 months ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

6 months ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

AbbVie’s Rinvoq cleared for giant cell arteritis in US

6 months ago talkbio0Tagged Approved, Giant Cell Arteritis, Inhibitor, Janus kinase, Rinvoq, Steroids, United States Food and Drug Administration, upadacitinib

Giant Cell Arteritis, Rinvoq, upadacitinib, Approved, Janus kinase, Inhibitor, United States Food and Drug Administration, Steroids

AIRNA nets $155M series B to launch clinical test of RNA editing tech

7 months ago talkbio0Tagged AIR-001, Airna, RNA, RNA Editing

RNA Editing, Airna, AIR-001, RNA

FDA clears Exelixis’ TKI for neuroendocrine tumours

7 months ago talkbio0Tagged Approved, Cabometyx, cabozantinib, Exelixis, Neoplasms, Neurosecretory Systems, Protein Tyrosine Kinase, United States Food and Drug Administration

CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor

J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso

7 months ago talkbio0Tagged Combined, Continuance of life, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso

Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso